Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, Shiraishi N, Raje N, Kumar S, Picker DH, Jacob GS, Richardson PG, Munshi NC, Anderson KC. Hamasaki M, et al. Among authors: neri p. Blood. 2005 Jun 1;105(11):4470-6. doi: 10.1182/blood-2004-09-3794. Epub 2005 Feb 10. Blood. 2005. PMID: 15705788 Free PMC article.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. Chauhan D, et al. Among authors: neri p. Blood. 2007 Feb 1;109(3):1220-7. doi: 10.1182/blood-2006-04-015149. Epub 2006 Oct 10. Blood. 2007. PMID: 17032924 Free PMC article.
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC. Ishitsuka K, et al. Among authors: neri p. Br J Haematol. 2008 May;141(5):598-606. doi: 10.1111/j.1365-2141.2008.07044.x. Epub 2008 Apr 7. Br J Haematol. 2008. PMID: 18397345 Free article.
Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Murray K, Culham M, Luider J, Fourie T, Rashid-Kolvear F, Bahlis NJ. Jimenez-Zepeda VH, et al. Among authors: neri p. Leuk Lymphoma. 2016;57(4):973-6. doi: 10.3109/10428194.2015.1085534. Epub 2015 Oct 8. Leuk Lymphoma. 2016. PMID: 26450458 No abstract available.
563 results